Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Retained Earnings To Equity Ratio for the quarter ending March 31, 2024: -1.22

Agios Pharm Retained Earnings To Equity Ratio is -1.22 for the quarter ending March 31, 2024, a -128.41% change year over year. The retained earnings to equity ratio measures the proportion of a company's retained earnings to its shareholders' equity. It is calculated by dividing the retained earnings by the shareholders' equity. This ratio provides insights into the company's reinvestment of earnings and the level of retained profits relative to shareholders' equity. A higher ratio suggests a higher proportion of earnings being retained for reinvestment or future distribution to shareholders.

Agios Pharm Retained Earnings To Equity Ratio for the quarter ending March 31, 2023 was -0.53, a -92.64% change year over year.
Agios Pharm Retained Earnings To Equity Ratio for the quarter ending March 31, 2022 was -0.28, a -2,156.39% change year over year.
Agios Pharm Retained Earnings To Equity Ratio for the quarter ending March 31, 2021 was 0.01, a 100.54% change year over year.
Agios Pharm Retained Earnings To Equity Ratio for the quarter ending March 31, 2020 was -2.49, a -28.90% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends